Rhythm Pharmaceuticals
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
- Founded
- 2008
- CEO
- Dr. David P. Meeker,M.D.
- Employees
- 414
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- rhythmtx.com
Company profile
- Exchange
- US
- Symbol
- RYTM
- Market-cap rank
- #1874
- Listing date
- 2017-10-05
- Market cap
- 7.79B
- Float cap
- 6.35B
- Shares out
- 69.33M
- Float shares
- 56.52M
Sectors & themes
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Rhythm Pharmaceuticals discussion 0 comments